TY - JOUR
T1 - Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia
AU - Jabbour, Elias J.
AU - Hughes, Timothy P.
AU - Cortés, Jorge E.
AU - Kantarjian, Hagop M.
AU - Hochhaus, Andreas
PY - 2014/7
Y1 - 2014/7
N2 - Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.
AB - Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.
KW - Drug resistance
KW - Myeloid leukemias and dysplasias
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84903461580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903461580&partnerID=8YFLogxK
U2 - 10.3109/10428194.2013.845883
DO - 10.3109/10428194.2013.845883
M3 - Review article
C2 - 24050507
AN - SCOPUS:84903461580
SN - 1042-8194
VL - 55
SP - 1451
EP - 1462
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -